Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsArizona Medicaid ETRA Prior Auth Policy | OpenPaye…
    Ask Trek AI about this page
    ModifiedArizona Complete HealthPolicy AZ.CP.PHAR.1012

    Clinical Policy: Endothelin Receptor Antagonists-ETRA (Letairis, Opsumit, Tracleer)

    Customize your policy alerts

    Sign up for Arizona Complete Health Policy AZ.CP.PHAR.1012 alerts

    Get alerted when Policy AZ.CP.PHAR.1012 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity criteria for ambrisentan (Letairis), bosentan (Tracleer), and macitentan (Opsumit) for Arizona Medicaid members with pulmonary arterial hypertension, including preferred-product requirements, sequencing, clinical criteria, documentation, contraindications, and approval durations.

    Policy Summary
    PayerArizona Complete Health
    PolicyEndothelin Receptor Antagonists (ETRA)
    Policy CodePolicy AZ.CP.PHAR.1012
    Change TypeModified
    Effective DateAug 18, 2019
    Last ReviewFeb 1, 2022
    Next Review DateN/A
    Key ActionSubmit clinical documentation supporting all applicable approval criteria when requesting prior authorization for ambrisentan, bosentan, or macitentan.
    SourceLink
    POLICY UPDATE CHANGES

    The 1Q 2020 annual review added maximum quantity per day information for the covered drugs.

    The 1Q 2022 annual review reported no significant changes and reviewed the references.

    The policy history added wording specifying that the criteria also apply to Care1st.

    3ETRA drugs covered
    6 monthsInitial approval
    12 monthsContinued-therapy approval

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >25 mm HgRequired mean PAP
    250 mg/dayTracleer maximum dose

    Coverage Criteria

    Initial Therapy

    Covered for pulmonary arterial hypertension when ALL of the following criteria are met:

    ALL of the following

    • Diagnosis of pulmonary arterial hypertension (PAH).
    • Prescribed by or in consultation with a cardiologist or pulmonologist.
    • Right heart catheterization (RHC) results show a mean pulmonary arterial pressure (PAP) > 25 mm Hg.> 25 mm Hg mean PAP
    • For Letairis and Tracleer requests: brand only.
    • For Opsumit requests: failure of Letairis AND Tracleer, unless contraindicated or clinically significant adverse effects are experienced.
    • One of the following

      • Failure of a calcium channel blocker (see Appendix B).
      • Inadequate response or contraindication to acute vasodilator testing.
      • Contraindication or clinically significant adverse effects to a calcium channel blocker.
    • Dose does not exceed the FDA-approved maximum recommended dose (see Section V).

    Continuation Therapy

    Continued pulmonary arterial hypertension therapy is covered when ALL of the following criteria are met:

    ALL of the following

    • Currently receiving the medication through the Centene benefit or previously met all initial approval criteria.
    • Member is responding positively to therapy.
    • If the request is for a dose increase, the new dose does not exceed the FDA-approved maximum recommended dose (see Section V).

    Non-FDA-approved indications not addressed in this policy are not authorized for coverage unless there is sufficient documentation of efficacy and safety according to the off-label use policies AZ.CP.PMN.53 for Arizona Medicaid.

    Clinical Thresholds

    Mean pulmonary arterial pressure
    MeasureMean pulmonary arterial pressure (PAP)
    Required resultGreater than 25 mm Hg
    Measurement methodRight heart catheterization (RHC)

    Prior Authorization and Provider Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for ambrisentan (Letairis), bosentan (Tracleer), and macitentan (Opsumit). Submit clinical documentation demonstrating that all applicable approval criteria are met.

    • AHCCCS preferred: brand Letairis and brand Tracleer.
    • AHCCCS non-preferred: generic ambrisentan, generic bosentan, and Opsumit.
    Step Therapy

    Calcium-Channel-Blocker Prerequisite

    Before an ETRA can be approved, document failure of a calcium-channel blocker unless the member qualifies for an exception.

    • Exception: inadequate response or contraindication to acute vasodilator testing.
    • Exception: contraindication or clinically significant adverse effects to a calcium-channel blocker.
    • Therapeutic alternatives include nifedipine, diltiazem, and amlodipine; applicable formulary restrictions and prior authorization requirements may apply.

    Clinical Background

    Endothelin receptor antagonists (ETRAs) are used to treat pulmonary arterial hypertension (PAH), primarily WHO Group 1 disease. The policy describes FDA-approved uses that include improving exercise ability, delaying clinical worsening or disease progression, reducing hospitalization risk, and improving pulmonary vascular resistance in specified patient populations. The supporting evidence primarily involves patients with WHO/NYHA functional class II through IV symptoms.

    Clinical Definitions and Classifications

    PAH
    AbbreviationPAH
    DefinitionPulmonary arterial hypertension
    WHO classificationGroup 1
    RHC
    AbbreviationRHC
    DefinitionRight heart catheterization
    Policy useUsed to measure mean pulmonary arterial pressure

    Initial Pulmonary Arterial Hypertension Therapy

    Initial Pulmonary Arterial Hypertension Therapy

    Initial therapy requires ALL of the following criteria:

    Initial pulmonary arterial hypertension therapy

    • Diagnosis of pulmonary arterial hypertension.
    • Prescription by or consultation with a cardiologist or pulmonologist.
    • Right heart catheterization results show a mean pulmonary arterial pressure greater than 25 mm Hg.>25 mm Hg mean PAP
    • For Letairis and Tracleer requests, the requested product is brand only.

    Continued Therapy

    Continued Therapy

    Continued therapy requires ALL of the following criteria:

    Continued therapy

    • The member is currently receiving the medication through the Centene benefit or previously met all initial approval criteria.
    • The member is responding positively to therapy.
    • If the request is for a dose increase, the new dose does not exceed the FDA-approved maximum recommended dose.FDA-approved maximum recommended dose

    ETRA Sequencing Requirements

    StepRequirementListed alternatives and exceptions
    1Try and fail a calcium-channel blocker before an endothelin receptor antagonist (ETRA).Nifedipine, diltiazem, or amlodipine. The prerequisite may be waived for an inadequate response or contraindication to acute vasodilator testing, or for a contraindication or clinically significant adverse effect from a calcium-channel blocker.
    StepRequirementException
    2Try and fail both Letairis (ambrisentan) and Tracleer (bosentan) before Opsumit (macitentan).The prerequisite may be waived when Letairis or Tracleer is contraindicated or causes clinically significant adverse effects.

    Maximum Daily Doses and Regimens

    Letairis (ambrisentan)
    DrugLetairis (ambrisentan)
    Listed regimen5 mg PO QD
    Maximum daily dose10 mg/day
    Tracleer (bosentan)
    DrugTracleer (bosentan)
    Listed titration regimenInitially 62.5 mg PO BID for 4 weeks, then increased to 125 mg PO BID
    Maximum daily dose250 mg/day
    Policy Summary
    PayerArizona Complete Health
    PolicyEndothelin Receptor Antagonists (ETRA)
    Policy CodePolicy AZ.CP.PHAR.1012
    Change TypeModified
    Effective DateAug 18, 2019
    Last ReviewFeb 1, 2022
    Next Review DateN/A
    Key ActionSubmit clinical documentation supporting all applicable approval criteria when requesting prior authorization for ambrisentan, bosentan, or macitentan.
    SourceLink
    On This Page
    Coverage CriteriaClinical ThresholdsPrior Authorization and Provider RequirementsClinical BackgroundClinical Definitions and ClassificationsInitial Pulmonary Arterial Hypertension TherapyContinued TherapyETRA Sequencing RequirementsMaximum Daily Doses and Regimens
    Step Therapy

    Opsumit Sequencing

    For Opsumit requests, document failure of both Letairis and Tracleer before requesting approval. Sequencing is not required when either medication is contraindicated or clinically significant adverse effects are experienced.

    • Letairis and Tracleer must be tried and failed unless a qualifying contraindication or intolerance is documented.
    Documentation Required

    Supporting Clinical Documentation

    Submit documentation supporting medical necessity and demonstrating that the member has met all applicable approval criteria.

    • Office chart notes.
    • Relevant laboratory results.
    • Other clinical information supporting the diagnosis, treatment history, response, contraindications, adverse effects, and medical necessity.
    Documentation Required

    Initial Request Evidence

    For an initial request, document pulmonary arterial hypertension and provide the prescriber or consulting specialist information and right heart catheterization results.

    • Diagnosis of pulmonary arterial hypertension.
    • Prescription by, or consultation with, a cardiologist or pulmonologist.
    • Right heart catheterization showing mean pulmonary arterial pressure (PAP) > 25 mm Hg.
    • For Letairis and Tracleer, request brand only.
    • For Opsumit, document failure of Letairis and Tracleer unless contraindicated or not tolerated.
    • Document calcium-channel-blocker failure or a qualifying exception.
    • Requested dose must not exceed the FDA-approved maximum recommended dose.
    • Initial approval duration: 6 months.
    Documentation Required

    Continuation Request Evidence

    For continuation requests, document that the member is receiving the medication through the Centene benefit or previously met all initial approval criteria and is responding positively to therapy.

    • Provide the current ETRA, dose, treatment status, and clinical response.
    • For a dose increase, document that the new dose does not exceed the FDA-approved maximum recommended dose.
    • Continuation approval duration: 12 months.
    Denial Risk

    Initial Approval Criteria Not Met

    An initial request may be denied when the diagnosis, prescriber qualifications, clinical evidence, sequencing, prerequisite therapy, product requirements, or dose limits do not meet policy criteria.

    • No documented PAH diagnosis.
    • Not prescribed by or in consultation with a cardiologist or pulmonologist.
    • Right heart catheterization does not show mean PAP > 25 mm Hg or results are not submitted.
    • Letairis or Tracleer is requested without the required brand-only product.
    • Opsumit is requested without documented Letairis and Tracleer failure, absent a documented contraindication or clinically significant adverse effect.
    • Calcium-channel-blocker failure or a qualifying exception is not documented.
    • Requested dose exceeds the FDA-approved maximum recommended dose.
    Denial Risk

    Unapproved Indication

    Coverage is not authorized for non-FDA-approved indications that are not addressed by this policy unless sufficient efficacy and safety documentation is provided under the applicable off-label use policy.

    • For Arizona Medicaid, refer to off-label use policy AZ.CP.PMN.53.
    • Submit documentation sufficient to support efficacy and safety for the requested off-label indication.
    Denial Risk

    Continuation Criteria Not Met

    A continuation request may be denied when the member is not receiving the medication through the applicable Centene benefit, has not met initial criteria, is not responding positively, or the requested dose exceeds the FDA-approved maximum.

    • Current therapy or prior satisfaction of all initial approval criteria is not documented.
    • Positive response to therapy is not demonstrated.
    • For a dose increase, the new dose exceeds the FDA-approved maximum recommended dose.
    PAP
    AbbreviationPAP
    DefinitionPulmonary arterial pressure
    Required thresholdMean PAP greater than 25 mm Hg
    WHO Group 1
    ClassificationWHO Group 1
    AbbreviationPAH
    DefinitionPulmonary arterial hypertension
    WHO Group 1
    ClassificationWHO Group 1
    ConditionPAH
    Expanded termPulmonary arterial hypertension
    WHO Group 2
    ClassificationWHO Group 2
    AbbreviationPH
    DefinitionPulmonary hypertension due to left heart disease
    WHO Group 3
    ClassificationWHO Group 3
    AbbreviationPH
    DefinitionPulmonary hypertension due to lung disease and/or hypoxemia
    WHO Group 4
    ClassificationWHO Group 4
    AbbreviationCTEPH
    DefinitionChronic thromboembolic pulmonary hypertension
    WHO Group 5
    ClassificationWHO Group 5
    AbbreviationPH
    DefinitionPulmonary hypertension due to unclear multifactorial mechanisms
    WHO/NYHA Functional Classes
    Class IComfortable at rest; no limitation; ordinary physical activity does not cause undue dyspnea or fatigue, chest pain, or near syncope
    Class IIComfortable at rest; slight limitation; ordinary physical activity causes undue dyspnea or fatigue, chest pain, or near syncope
    Class IIIComfortable at rest; marked limitation; less-than-ordinary physical activity causes undue dyspnea or fatigue, chest pain, or near syncope
    Class IVInability to carry out any physical activity without symptoms; discomfort is increased by any physical activity
    For Opsumit requests, the member has failed Letairis AND Tracleer, unless either product is contraindicated or associated with clinically significant adverse effects.
  1. ALL of the following

    • At least one exception

      • The member has an inadequate response or contraindication to acute vasodilator testing.
      • The member has a contraindication or clinically significant adverse effect from a calcium channel blocker.
  2. The dose does not exceed the FDA-approved maximum recommended dose.
  3. Opsumit (macitentan)
    DrugOpsumit (macitentan)
    Listed regimen10 mg PO QD
    Maximum daily dose10 mg/day